{"id":"paroxetine-cr","safety":{"commonSideEffects":[{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"10-15%","effect":"Somnolence"},{"rate":"10-20%","effect":"Sexual dysfunction"},{"rate":"5-10%","effect":"Sweating"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6067650","moleculeType":"Small molecule","molecularWeight":"749.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The CR (controlled-release) formulation provides sustained drug delivery over 24 hours.","oneSentence":"Paroxetine CR selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:49.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT00648427","phase":"PHASE1","title":"Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-04","conditions":"Healthy","enrollment":75},{"nctId":"NCT00647881","phase":"PHASE1","title":"Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-04","conditions":"Healthy","enrollment":75},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05637671","phase":"PHASE3","title":"Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-02-10","conditions":"Vasomotor Symptoms","enrollment":146},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00836069","phase":"PHASE3","title":"Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2008-10","conditions":"Anxiety Disorders","enrollment":5},{"nctId":"NCT00429169","phase":"PHASE4","title":"Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Depression","enrollment":101},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT00202449","phase":"NA","title":"Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2004-07","conditions":"Stress Disorders, Post-Traumatic, Sleep Disorders","enrollment":59},{"nctId":"NCT01339247","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil - Fed Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":"Depressive Disorder","enrollment":60},{"nctId":"NCT01316926","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-09","conditions":"Depressive Disorder","enrollment":60},{"nctId":"NCT01000857","phase":"PHASE1","title":"Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-05","conditions":"Depressive Disorder","enrollment":26},{"nctId":"NCT01748955","phase":"PHASE4","title":"Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-06","conditions":"Depression, Suicidal Ideation","enrollment":15},{"nctId":"NCT00406003","phase":"PHASE1","title":"Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03-24","conditions":"Depressive Disorder","enrollment":6},{"nctId":"NCT00406432","phase":"PHASE1","title":"A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-09","conditions":"Depressive Disorder","enrollment":12},{"nctId":"NCT00049972","phase":"PHASE4","title":"Major Depressive Disorder Study In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Major Depressive Disorder","enrollment":646},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT00749359","phase":"PHASE1","title":"PAXIL CR Bioequivalence Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-07","conditions":"Depressive Disorder","enrollment":166},{"nctId":"NCT00672776","phase":"PHASE4","title":"Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":40},{"nctId":"NCT00866294","phase":"PHASE3","title":"Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Depressive Disorder","enrollment":416},{"nctId":"NCT00067444","phase":"PHASE3","title":"Depression Study In Elderly Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":560},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT00062738","phase":"PHASE2","title":"Treatment of Depression in Parkinson's Disease Trial","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2003-06","conditions":"Parkinson Disease, Depression","enrollment":52},{"nctId":"NCT00249847","phase":"NA","title":"Study of PET Scans and Serotonin in Hot Flashes Treatment","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Hot Flashes","enrollment":5},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT01916200","phase":"PHASE4","title":"Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-01","conditions":"Depressive Disorder","enrollment":""},{"nctId":"NCT00121888","phase":"PHASE1, PHASE2","title":"Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2002-12","conditions":"Stress Disorders, Post-Traumatic","enrollment":60},{"nctId":"NCT00113295","phase":"PHASE4","title":"Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-02","conditions":"Anxiety Disorder","enrollment":50},{"nctId":"NCT00610909","phase":"PHASE4","title":"Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-01","conditions":"Irritable Bowel Syndrome","enrollment":60},{"nctId":"NCT00610610","phase":"PHASE4","title":"Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-01","conditions":"Fibromyalgia Syndrome","enrollment":120},{"nctId":"NCT00215163","phase":"PHASE2, PHASE3","title":"Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-12","conditions":"Stress Disorders, Post-Traumatic","enrollment":17},{"nctId":"NCT01130103","phase":"PHASE4","title":"Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack","status":"COMPLETED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2004-03","conditions":"Posttraumatic Stress Disorder","enrollment":37},{"nctId":"NCT01357967","phase":"PHASE4","title":"The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope","status":"UNKNOWN","sponsor":"Inje University","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT00368303","phase":"PHASE3","title":"A Local Register Study For Major Depression Of Paroxetine Controlled Release","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":362},{"nctId":"NCT00767754","phase":"PHASE4","title":"Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2007-01","conditions":"Panic Disorder","enrollment":37},{"nctId":"NCT00225914","phase":"PHASE4","title":"Study of Paxil Use in Menopausal Women","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-09","conditions":"Menopause","enrollment":64},{"nctId":"NCT00229528","phase":"PHASE4","title":"Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2004-03","conditions":"Coronary Artery Disease","enrollment":25},{"nctId":"NCT00330239","phase":"PHASE4","title":"Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-01","conditions":"PTSD","enrollment":25},{"nctId":"NCT00492414","phase":"PHASE4","title":"Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release","status":"UNKNOWN","sponsor":"Inje University","startDate":"","conditions":"Panic Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paxil CR","Paxil"],"phase":"marketed","status":"active","brandName":"Paroxetine CR","genericName":"Paroxetine CR","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paroxetine CR selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}